22 / 31
Peeters M, et al. Eur J Cancer 2013;49(Suppl 4):abstract MC13-0024 (and poster).
WT
RAS
= WT
KRAS
and
NRAS
exons 2, 3, 4.
Events
n (%)
Median months
(95% CI)
Pmab + FOLFOX4 39 (71)
40.0
FOLFOX4
41 (91)
36.2
Events
n (%)
Median, months
(95% CI)
Pmab +FOLFOX4
91 (80)
26.0
FOLFOX4
117 (87)
20.6
‒ anti-VEGF
+ anti-VEGF
HR = 0.69 (95% CI, 0.53–0.92)
P = 0.0096
HR = 0.64 (95% CI, 0.41–1.00)
P = 0.0494
0
20
40
60
80
100
90
70
50
30
10
Months
0
36
4
8 12 16 20 24 28 32
40 44 48 52 56 60 64 68
Months
0
20
40
60
80
100
90
70
50
30
10
0
36
4 8 12 16 20 24 28 32
68
40 44 48 52 56 60 64
Proportion surviving, %
PRIME: OS by post-progression anti-VEGF therapy (wt
RAS
)